XORTX Therapeutics Inc. (XRTX)
NASDAQ: XRTX · IEX Real-Time Price · USD
3.700
+0.120 (3.35%)
Mar 28, 2024, 4:00 PM EDT - Market closed

XORTX Therapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for XORTX Therapeutics stock has a target of 14, which predicts an increase of 278.38% from the current stock price of 3.70.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $14 $14 $14 $14
Change +278.38% +278.38% +278.38% +278.38%
* Price targets were last updated on Jan 4, 2024.

Analyst Ratings

According to 1 stock analyst, the rating for XRTX is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Jan '24Feb '24Mar '24
Strong Buy 111
Buy 000
Hold 000
Sell 000
Strong Sell 000
Total 111

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Alliance Global Partners
Alliance Global Partners
Strong Buy
Maintains
$9$14
Strong Buy Maintains $9$14 +278.38% Jan 4, 2024
Alliance Global Partners
Alliance Global Partners
Strong Buy
Initiates
$99
Strong Buy Initiates $99 +2,575.68% Dec 9, 2021
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.42
from -6.39
EPS Next Year
-1.39
from -1.42
Year 2019202020212022202320242025
Revenue
-------
Revenue Growth
-------
EPS
-1.08-1.71-1.53-6.39-1.42-1.39-1.55
EPS Growth
-------
No. Analysts ----233
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 202320242025
High n/a n/a n/a
Avg n/a n/a n/a
Low n/a n/a n/a

Revenue Growth

Revenue Growth 202320242025
High - - -
Avg - - -
Low - - -

EPS Forecast

EPS 202320242025
High -1.48 -1.16 -1.00
Avg -1.42 -1.39 -1.55
Low -1.38 -1.62 -2.08

EPS Growth

EPS Growth 202320242025
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.